AIMS/HYPOTHESIS: Growth hormone has been used experimentally in two studies to treat individuals with type 2 diabetes, with both reporting beneficial effects on glucose metabolism. However, concerns over potential diabetogenic actions of growth hormone complicate its anticipated use to treat type 2 diabetes. Thus, an animal model of type 2 diabetes could help evaluate the effects of growth hormone for treating this condition. METHODS: Male C57BL/6J mice were placed on a high-fat diet to induce obesity and type 2 diabetes. Starting at 16 weeks of age, mice were treated once daily for 6 weeks with one of four different doses of growth hormone. Body weight, body composition, fasting blood glucose, insulin, glucose tolerance, liver triacylglycerol, tissue weights and blood chemistries were determined. RESULTS: Body composition measurements revealed a dose-dependent decrease in fat and an increase in lean mass. Analysis of fat loss by depot revealed that subcutaneous and mesenteric fat was the most sensitive to growth hormone treatment. In addition, growth hormone treatment resulted in improvement in glucose metabolism, with the highest dose normalising glucose, glucose tolerance and liver triacylglycerol. In contrast, insulin levels were not altered by the treatment, nor did organ weights change. However, fasting plasma leptin and resistin were significantly decreased after growth hormone treatment. CONCLUSIONS/ INTERPRETATION: Growth hormone therapy improves glucose metabolism in this mouse model of obesity and type 2 diabetes, providing a means to explore the molecular mechanism(s) of this treatment.
AIMS/HYPOTHESIS: Growth hormone has been used experimentally in two studies to treat individuals with type 2 diabetes, with both reporting beneficial effects on glucose metabolism. However, concerns over potential diabetogenic actions of growth hormone complicate its anticipated use to treat type 2 diabetes. Thus, an animal model of type 2 diabetes could help evaluate the effects of growth hormone for treating this condition. METHODS: Male C57BL/6J mice were placed on a high-fat diet to induce obesity and type 2 diabetes. Starting at 16 weeks of age, mice were treated once daily for 6 weeks with one of four different doses of growth hormone. Body weight, body composition, fasting blood glucose, insulin, glucose tolerance, liver triacylglycerol, tissue weights and blood chemistries were determined. RESULTS: Body composition measurements revealed a dose-dependent decrease in fat and an increase in lean mass. Analysis of fat loss by depot revealed that subcutaneous and mesenteric fat was the most sensitive to growth hormone treatment. In addition, growth hormone treatment resulted in improvement in glucose metabolism, with the highest dose normalising glucose, glucose tolerance and liver triacylglycerol. In contrast, insulin levels were not altered by the treatment, nor did organ weights change. However, fasting plasma leptin and resistin were significantly decreased after growth hormone treatment. CONCLUSIONS/ INTERPRETATION:Growth hormone therapy improves glucose metabolism in this mouse model of obesity and type 2 diabetes, providing a means to explore the molecular mechanism(s) of this treatment.
Authors: Niels Jessen; Christian B Djurhuus; Jens O L Jørgensen; Lasse S Jensen; Niels Møller; Sten Lund; Ole Schmitz Journal: Am J Physiol Endocrinol Metab Date: 2004-08-31 Impact factor: 4.310
Authors: Juan-Pablo del Rincon; Keiji Iida; Bruce D Gaylinn; Carrie E McCurdy; J Wayne Leitner; Linda A Barbour; John J Kopchick; Jacob E Friedman; Boris Draznin; Michael O Thorner Journal: Diabetes Date: 2007-03-15 Impact factor: 9.461
Authors: Jonathan A Young; Brooke E Henry; Fabian Benencia; Stephen Bell; Edward O List; John J Kopchick; Darlene E Berryman Journal: J Neuroendocrinol Date: 2020-04-29 Impact factor: 3.627
Authors: Nicoleta C Olarescu; Darlene E Berryman; Lara A Householder; Ellen R Lubbers; Edward O List; Fabian Benencia; John J Kopchick; Jens Bollerslev Journal: J Endocrinol Date: 2015-05-05 Impact factor: 4.286
Authors: Edward O List; Darlene E Berryman; Mathew Buchman; Caitlin Parker; Kevin Funk; Stephen Bell; Silvana Duran-Ortiz; Yanrong Qian; Jonathan A Young; Cody Wilson; Julie Slyby; Savannah McKenna; Elizabeth A Jensen; John J Kopchick Journal: Endocrinology Date: 2019-01-01 Impact factor: 4.736
Authors: Edward O List; Darlene E Berryman; Kevin Funk; Elahu S Gosney; Adam Jara; Bruce Kelder; Xinyue Wang; Laura Kutz; Katie Troike; Nicholas Lozier; Vincent Mikula; Ellen R Lubbers; Han Zhang; Clare Vesel; Riia K Junnila; Stuart J Frank; Michal M Masternak; Andrzej Bartke; John J Kopchick Journal: Mol Endocrinol Date: 2013-01-24
Authors: Kayla Raider; Delin Ma; Janna L Harris; Isabella Fuentes; Robert S Rogers; Joshua L Wheatley; Paige C Geiger; Hung-Wen Yeh; In-Young Choi; William M Brooks; John A Stanford Journal: Neurochem Int Date: 2016-04-26 Impact factor: 3.921